Schlegel, Eugen
2 papers on CoChat
Most cited papers
- Verified
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet
Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling
Cited by 942
- Verified
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology
Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments
Cited by 130
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free